Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BBO-10203 · 1 trial · 11 indications
| Arm | Type | Description |
|---|---|---|
| BBO-10203 | EXPERIMENTAL | Participants enrolled in this cohort will receive BBO-10203 tablets orally (different dose levels will be evaluated) once daily as monotherapy. This cohort will enroll patients with HER2-positive advanced breast cancer, HR-positive HER2-negative advanced breast cancer, advanced colorectal cancer, and advanced lung cancer. |
| BBO-10203 + Trastuzumab | EXPERIMENTAL | Participants enrolled in this cohort will receive BBO-10203 tablets orally in combination with trastuzumab. This cohort will enroll patients with HER2-positive advanced breast cancer. |
| BBO-10203 + Fulvestrant | EXPERIMENTAL | Participants enrolled in this cohort will receive BBO-10203 tablets orally in combination with fulvestrant. This cohort will enroll patients with HR-positive, HER2-negative advanced breast cancer. |
| BBO10203 + Fulvestrant + Ribociclib | EXPERIMENTAL | Participants enrolled in this cohort will receive BBO-10203 tablets orally in combination with fulvestrant and ribociclib as determined in the dose escalation. This cohort will enroll patients with HR-positive, HER2-negative advanced breast cancer. |
| BBO10203 + FOLFOX + Bevacizumab | EXPERIMENTAL | Participants enrolled in this cohort will receive BBO-10203 tablets orally in combination with FOLFOX and bevacizumab. This cohort will enroll patients with KRAS-mutant advanced colorectal cancer. |
| Name | Type | Description |
|---|---|---|
| BBO-10203 | DRUG | Participants will receive assigned dose of BBO-10203 orally once daily |
| Trastuzumab | DRUG | Participants will receive trastuzumab as infusion or subcutaneous injection every 21 days |
| Fulvestrant | DRUG | Patients will receive Fulvestrant as an intramuscular injection every 28 days (additional dose on C1D15) |
| Ribociclib | DRUG | Patients will receive Ribociclib orally once a day (21 days on treatment, 7 days off) |
| FOLFOX | DRUG | Patients will receive FOLFOX as infusion every 14 days |
| Bevacizumab | DRUG | Patients will receive bevacizumab as infusion every 28 days |
Inclusion Criteria: * Locally advanced and unresectable or metastatic HER2-positive advanced breast cancer (aBC), HR-positive/HER2-negative advanced breast cancer, KRAS mutant advanced colorectal cancer (aCRC), or KRAS mutant advanced non-small cell lung cancer (aNSCLC) * Measurable disease by RECI...
BBO-10203 is an investigational small molecule being developed for the treatment of advanced solid tumors in adults. It is currently in Phase 1 clinical development for conditions including metastatic breast cancer, metastatic lung cancer, metastatic colorectal cancer, and other advanced solid tumors.
BBO-10203 targets PI3Kα, a protein involved in cell growth and survival pathways. By inhibiting this target, the drug aims to interfere with tumor cell proliferation in advanced solid tumors.
BBO-10203 is being developed by BridgeBio Oncology Therapeutics, Inc., a biopharmaceutical company. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with advanced solid tumors.
BBO-10203 is in Phase 1 clinical development. It is an investigational drug that has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to assess the drug's safety, tolerability, and preliminary efficacy.
BBO-10203 is being studied in an open-label Phase 1 clinical trial with the identifier NCT06625775. This trial is recruiting approximately 392 participants with advanced solid tumors, including metastatic breast cancer, lung cancer, and colorectal cancer, across the United States, Australia, Brazil, France, and Spain.